Regentis Biomaterials Gets Approval for Cartilage Product Manufacturing Process From European Regulator

MT Newswires Live
07/15

Regentis Biomaterials (RGNT) has obtained approval from the European Notified Body to manufacture its knee cartilage repair product GelrinC using its next-generation solvent-free manufacturing process, the company said Wednesday.

The manufacturing process increases production yield fivefold and improves efficiency and scalability, the company said.

Regentis prepares to commercially launch the product in Europe, it said.

Price: 2.59, Change: +0.09, Percent Change: +3.56

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10